2021
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness
Metzger-Filho O, Collier K, Asad S, Ansell PJ, Watson M, Bae J, Cherian M, O’Shaughnessy J, Untch M, Rugo HS, Huober JB, Golshan M, Sikov WM, von Minckwitz G, Rastogi P, Li L, Cheng L, Maag D, Wolmark N, Denkert C, Symmans WF, Geyer CE, Loibl S, Stover DG. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. Npj Breast Cancer 2021, 7: 142. PMID: 34764307, PMCID: PMC8586340, DOI: 10.1038/s41523-021-00349-y.Peer-Reviewed Original ResearchTriple-negative breast cancerNeoadjuvant chemotherapyCohort studyBreast cancerInstability scoreGenomic instability scoreGermline BRCA mutation carriersPathologic complete response rateAddition of carboplatinComplete response rateStandard neoadjuvant chemotherapyLymph node statusBRCA mutation carriersGermline BRCA1/2 mutationsNegative breast cancerOverall cohortNode statusTreatment armsHigher oddsMutation carriersBRCA1/2 mutationsResponse rateCarboplatinPARP inhibitorsCancer
2009
Factors affecting surgical decision-making in patients undergoing BRCA1/2 testing at breast cancer diagnosis.
Stadler Z, Stoeckert K, Perez A, Regan M, Golshan M, Garber J. Factors affecting surgical decision-making in patients undergoing BRCA1/2 testing at breast cancer diagnosis. Cancer Research 2009, 69: 1095. DOI: 10.1158/0008-5472.sabcs-1095.Peer-Reviewed Original ResearchBilateral mastectomyFamily cancer historyPre-test probabilityBC patientsBRCA1/2 mutationsBreast MRIBreast conservationIndependent predictorsSurgical treatmentCancer historyBC diagnosisBreast cancerEarly-stage breast cancerDana-Farber Cancer InstituteLogistic regressionPositive genetic test resultAbnormal MRI resultsDeleterious BRCA1/2 mutationsAbnormal MRI findingsDefinitive surgical treatmentBRCA1/2 germline mutationsTest-negative patientsTime of diagnosisStage breast cancerStrong independent predictor